

10/508483463
R06A PCT/PTO 10 SEP 2004

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 03/082918 A1

(51) International Patent Classification⁷: C07K 14/475,
A61K 38/18, 38/12

University College London, The Cruciform Building,
Gower Street, London WC1E 6AU (GB).

(21) International Application Number: PCT/GB03/01375

(74) Agent: GILL JENNINGS & EVERY; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).

(22) International Filing Date: 28 March 2003 (28.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0207644.6 2 April 2002 (02.04.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): ARK
THERAPEUTICS LTD. [GB/GB]; 1 Fitzroy Mews,
London W1T 6DE (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SELWOOD, David
[GB/GB]; Wolfson Institute for Biomedical Research, Uni-
versity College London, The Cruciform Building, Gower
Street, London WC1E 6AU (GB). LÖHR, Marianne
[DE/GB]; Wolfson Institute for Biomedical Research,
University College London, The Cruciform Building,
Gower Street, London WC1E 6AU (GB). ZACHARY,
Ian [GB/GB]; Wolfson Institute for Biomedical Research,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: VEGF PEPTIDES AND THEIR USE

(57) Abstract: A novel peptide having the amino acid sequence SCKNTDSRCKARQLELNERTCRCDKPRR or a fragment thereof
that substantially retains NP-1 antagonist activity, in cyclic form, is proposed for use in therapy.

WO 03/082918 A1

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/01375

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/475 A61K38/18 A61K38/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HAIYAN JIA ET AL: "PEPTIDES ENCODED BY EXON 6 OF VEGF INHIBIT ENDOTHELIAL CELL BIOLOGICAL RESPONSES AND ANGIOGENESIS INDUCED BY VEGF" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 283, no. 1, 2001, pages 164-173, XP002941058 ISSN: 0006-291X</p> <p style="text-align: center;">--- -/--</p>	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

27 June 2003

Date of mailing of the international search report

16/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Grosskopf, R

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SOKER S ET AL: "Characterization of novel Vascular Endothelial Growth Factor (VEGF) Receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5761-5767, XP002097905 ISSN: 0021-9258 cited in the application</p>	
A	<p>WO 99 29861 A (KLAGSBRUN MICHAEL ;SOKER SHAY (US); CHILDRENS MEDICAL CENTER (US)) 17 June 1999 (1999-06-17) see the whole document</p>	
A	<p>SOKER S ET AL: "Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon7-encoded domain of VEGF165" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 50, 12 December 1997 (1997-12-12), pages 31582-31588, XP002098056 ISSN: 0021-9258 cited in the application see especially page 31585, left column</p>	
A	<p>WO 93 08473 A (BETH ISRAEL HOSPITAL) 29 April 1993 (1993-04-29) see sequence of Claim 8: it is 100% identical with the claimed peptide from position 10 to 29</p>	
P,A	<p>BAINBRIDGE JAMES W B ET AL: "A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 302, no. 4, 21 March 2003 (2003-03-21), pages 793-799, XP002245130 ISSN: 0006-291X</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01375

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9929861	A	17-06-1999	AU 1633999 A	28-06-1999
			AU 1810499 A	28-06-1999
			AU 1810899 A	28-06-1999
			AU 1906099 A	28-06-1999
			CA 2313348 A1	17-06-1999
			CA 2313390 A1	17-06-1999
			CA 2313607 A1	17-06-1999
			EP 1037981 A1	27-09-2000
			EP 1037925 A2	27-09-2000
			EP 1037994 A1	27-09-2000
			JP 2002505078 T	19-02-2002
			JP 2001526032 T	18-12-2001
			WO 9929861 A1	17-06-1999
			WO 9929729 A2	17-06-1999
			WO 9930157 A2	17-06-1999
			WO 9929858 A1	17-06-1999
			US 2002132774 A1	19-09-2002
			US 2003104532 A1	05-06-2003
WO 9308473	A	29-04-1993	AU 2874292 A	21-05-1993
			PT 101008 A	28-02-1994
			WO 9308473 A1	29-04-1993
			ZA 9208218 A	30-04-1993